Telomere / telomerase evidence reference
TeloiX
Telomere attrition, telomerase, shelterin, the length-as-biomarker problem and the telomerase-cancer paradox — mapped to what the evidence actually shows, species by species, endpoint by endpoint.
Human data exists, but no telomere intervention has a healthy-aging lifespan RCT. What exists is telomere-length / telomerase-activity biomarker data (TA-65), clinical outcomes in a rare telomere DISEASE (danazol; nandrolone), a small cancer-cohort pilot (Ornish), and gene-therapy lifespan data in mice (AAV-TERT). "Changed a telomere number in a trial" is not "extended healthy human lifespan."
Two hard truths the field glosses over. (1) Telomere length is a contested aging biomarker — measurement varies by method and tissue, and "longer" is not simply "healthier." (2) Activating telomerase is not risk-free — it raises an unresolved cancer-risk question, and the only FDA-approved telomerase drug, imetelstat (RYTELO, 2024), inhibits telomerase to treat cancer — the opposite direction from anti-aging "activation."
Interventions
Intervention
TA-65 (cycloastragenol)
Intervention
Danazol (androgen)
Intervention
Comprehensive lifestyle change (Ornish)
Intervention
Telomerase gene therapy (AAV-TERT)
Intervention
Imetelstat (telomerase INHIBITOR)
Intervention
Astragalus / cycloastragenol (raw)
Study records
Study
TA-65 lengthens telomeres in a 1-year RCT (Salvador et al., 2016)
Study
TA-65 and immune / telomere markers in a health-maintenance program (Harley et al., 2011)
Study
TA-65 telomere-length meta-analysis (claimed 2025) — UNVERIFIED
Study
Danazol reduces telomere attrition in telomere disease (Townsley et al., 2016)
Study
Nandrolone: telomere elongation and clinical improvement in telomeropathy (Clé et al., 2019)
Study
Comprehensive lifestyle change increases telomerase activity — pilot (Ornish et al., 2008)
Study
Lifestyle change and telomere length: 5-year follow-up (Ornish et al., 2013)
Study
AAV-TERT gene therapy delays aging and increases mouse lifespan (Bernardes de Jesus et al., 2012)
Study
Telomerase gene therapy in a short-telomere pulmonary-fibrosis mouse model (Povedano et al., 2018)
Study
IMerge Phase 3: imetelstat (telomerase INHIBITOR) in lower-risk MDS (Platzbecker et al., 2024)
Study
Leukocyte telomere length and mortality in 64,637 individuals (Rode et al., 2015)
Mechanisms
Mechanism
Telomere attrition as a hallmark of aging
Mechanism
Telomeres and the end-replication problem
Mechanism
Telomerase (TERT / TERC)
Mechanism
Shelterin complex
Mechanism
Replicative senescence and the Hayflick limit
Mechanism
T-loop and telomere end structure
Mechanism
ALT (alternative lengthening of telomeres)
Mechanism
Telomere length as a biomarker (and why length is not health)
Mechanism
The telomerase–cancer paradox
Evidence tiers
| Tier | Label | Note |
|---|---|---|
| 1 | Healthy-aging human lifespan RCT | Randomized, hard lifespan/healthy-aging endpoint in a healthy-aging population. NONE exist for any telomere intervention as of the search date — tier empty by design. |
| 2 | Human clinical-outcome RCT — disease population | Randomized, hard clinical outcome but in a disease population, not healthy aging. Examples: danazol in telomeropathy/marrow failure; imetelstat (a telomerase INHIBITOR) in lower-risk MDS. |
| 3 | Human RCT — telomere-length / telomerase-activity biomarker endpoint | Randomized, endpoint is a contested telomere biomarker (telomere length or telomerase activity), not a clinical outcome or lifespan. Example: TA-65 telomere-length RCT (Salvador 2016). |
| 4 | Human pilot / observational — biomarker | Small pilot or observational cohort with a telomere biomarker endpoint; no randomized healthy-aging intervention. Examples: Ornish lifestyle pilot; telomere-length↔mortality cohorts (association only, contested). |
| 5 | Animal lifespan study | Lifespan change in an animal model, e.g. AAV-TERT telomerase gene therapy in mice (delayed aging, increased longevity, no rise in cancer). |
| 6 | Animal healthspan / disease-model / mechanism | Healthspan, function, or disease-model change in an animal (e.g. telomerase gene therapy in a mouse pulmonary-fibrosis model); no whole-organism lifespan endpoint. |
| 7 | In vitro / mechanism | Cell-culture or biochemical mechanism (telomerase enzymology, shelterin, T-loop, ALT); no whole-organism outcome. |